Alarmins and antimicrobial immunity

References

• Yang D, Oppenheim JJ. Antimicrobial proteins act as ‘alarmins’ in joint immune defense. Arthritis Rheum 2004; 50: 3401–3403
   PubMed Web of Science ®Google Scholar
• Oppenheim JJ, Yang D. Alarmins: chemotactic activators of immune responses. Curr Opin Immunol 2005; 17: 359–365
   PubMed Web of Science ®Google Scholar
• Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003; 3: 710–720
   PubMed Web of Science ®Google Scholar
• Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol 2004; 75: 39–48
   PubMed Web of Science ®Google Scholar
• Rosenberg HF, Domachowke JB. Eosinophils, eosinophil ribonucleases, and their role in host defense against respiratory virus pathogens. J Leukoc Biol 2001; 70: 691–698
   PubMed Web of Science ®Google Scholar
• Hock R, Furusawa T, Ueda T, Bustin M. HMG chromosomal proteins in development and disease. Trends Cell Biol 2007; 17: 72–79
   PubMed Web of Science ®Google Scholar
• Yang D, Biragyn A, Hoover DM, Lubkowski J, Oppenheim JJ. Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu Rev Immunol 2004; 22: 181–315
   PubMed Web of Science ®Google Scholar
• Ganz T, Selsted ME, Szklarek D, et al. Defensins: natural peptide antibiotics of human neutrophils. J Clin Invest 1985; 76: 1427–1435
   PubMed Web of Science ®Google Scholar
• Ouellette AJ, Selsted ME. Paneth cell defensins: endogenous peptide components of intestinal host defense. FASEB J 1996; 10: 1280–1289
   PubMed Web of Science ®Google Scholar
• Schutte BC, Mitros JP, Bartlett JA, et al. Discovery of five conserved beta -defensin gene clusters using a computational search strategy. Proc Natl Acad Sci USA 2002; 99: 2129–2133
   PubMed Web of Science ®Google Scholar
• Tang Y-Q, Yuan J, Osapay G, et al. A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated a-defensins. Science 1999; 286: 498–502
   PubMed Web of Science ®Google Scholar
• Kaiser V, Diamond G. Expression of mammalian defensin genes. J Leukoc Biol 2000; 68: 779–784
   PubMed Web of Science ®Google Scholar
• Chertov O, Michiel DF, Xu L, et al. Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem 1996; 271: 2935–2940
   PubMed Web of Science ®Google Scholar
• Yang D, Chertov O, Bykovskaia SN, et al. b-Defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999; 286: 525–528
   PubMed Web of Science ®Google Scholar
• Yang D, Chen Q, Chertov O, Oppenheim JJ. Human neutrophil defensins selectively chemoattract naïve T and immature dendritic cells. J Leukoc Biol 2000; 68: 9–14
   PubMed Web of Science ®Google Scholar
• Niyonsaba F, Iwabuchi K, Matsuda H, Ogawa H, Nagaoka I. Epithelial cell-derived human b-defensin-2 acts as a chemotaxin for mast cells through a pertussis toxin-sensitive and phospholipase C-dependent pathway. Int Immunol 2002; 14: 421–426
   PubMed Web of Science ®Google Scholar
• Niyonsaba F, Ogawa H, Nagaoka I. Human b-defensin-2 functions as a chemotactic agent for tumour necrosis factor-alpha-treated human neutrophils. Immunology 2004; 111: 273–281
   PubMed Web of Science ®Google Scholar
• Wu Z, Hoover DM, Yang D, et al. Engineering disulfide bridges to dissect antimicrobial and chemotactic activities of human b-defensin 3. Proc Natl Acad Sci USA 2003; 100: 8880–8885
   PubMed Web of Science ®Google Scholar
• Biragyn A, Surenhu M, Yang D, et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol 2001; 167: 6644–6653
   PubMed Web of Science ®Google Scholar
• Garcia JR, Jaumann F, Schulz S, et al. Identification of a novel, multifunctional b-defensin (human b-defensin 3) with specific antimicrobial activity: its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res 2001; 306: 257–264
   PubMed Web of Science ®Google Scholar
• Conejo-Garcia JR, Benencia F, Courreges MC, et al. Tumor-infiltrating dendritic cell precursors recruited by a b-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 2004; 10: 950–958
   PubMed Web of Science ®Google Scholar
• Niyonsaba F, Someya A, Hirata M, Ogawa H, Nagaoka I. Evaluation of the effects of peptide antibiotics human b-defensin-1/2 and LL-37 on histamine release and prostaglandin D2 production from mast cells. Eur J Immunol 2001; 31: 1066–1075
   PubMed Web of Science ®Google Scholar
• Niyonsaba F, Ushio H, Nagaoka I, Okumura K, Ogawa H. The human beta-defensins (−1, −2, −3, −4) and cathelicidin LL-37 induce IL-18 secretion through p38 and ERK MAPK activation in primary human keratinocytes. J Immunol 2005; 175: 1776–1784
   PubMed Web of Science ®Google Scholar
• Yamashita T, Saito K. Purification, primary structure, and biological activity of guinea pig neutrophil cationic peptides. Infect Immun 1989; 57: 2405–2409
   PubMed Web of Science ®Google Scholar
• Befus AD, Mowat C, Gilchrist M, et al. Neutrophil defensins induce histamine secretion from mast cells: mechanisms of action. J Immunol 1999; 163: 947–953
   PubMed Web of Science ®Google Scholar
• van Wetering S, Mannesse-Lazeroms SPG, Dijkman JH, Hiemstra PS. Effect of neutrophil serine proteinases and defensins on lung epithelial cells: modulation of cytotoxicity and IL-8 production. J Leukoc Biol 1997; 62: 217–226
   PubMed Web of Science ®Google Scholar
• Niyonsaba F, Ushio H, Nakano N, et al. Antimicrobial peptides human b-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J Invest Dermatol 2007; 127: 594–604
   PubMed Web of Science ®Google Scholar
• Biragyn A, Ruffini PA, Leifer CA, et al. Toll-like receptor 4-dependent activation of dendritic cells by b-defensin 2. Science 2002; 298: 1025–1029
   PubMed Web of Science ®Google Scholar
• Funderburg N, Lederman MM, Feng Z, et al. Human-defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proc Natl Acad Sci USA 2007; 104: 18631–18635
   PubMed Web of Science ®Google Scholar
• Zanetti M, Gennaro R, Romeo D. Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 1995; 374: 1–5
   PubMed Web of Science ®Google Scholar
• Larrick JW, Hirata M, Zheng H, et al. A novel granulocyte-derived peptide with lipopolysaccharide-neutralizing activity. J Immunol 1994; 152: 231–240
   PubMed Web of Science ®Google Scholar
• Gallo RL, Kim KJ, Bernfield M, et al. Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse. J Biol Chem 1997; 272: 13088–13093
   PubMed Web of Science ®Google Scholar
• Agerberth B, Gunne H, Odeberg J, et al. FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. Proc Natl Acad Sci USA 1995; 92: 195–199
   PubMed Web of Science ®Google Scholar
• Bals R, Wang X, Zasloff M, Wilson JM. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad anti-microbial activity at the airway surface. Proc Natl Acad Sci USA 1998; 95: 9541–9546
   PubMed Web of Science ®Google Scholar
• Dorschner RA, Pestonjamasp VK, Tamakuwala S, et al. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J Invest Dermatol 2001; 117: 91–97
   PubMed Web of Science ®Google Scholar
• Di Nardo A, Vitiello A, Gallo RL. Cutting Edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J Immunol 2003; 170: 2274–2278
   PubMed Web of Science ®Google Scholar
• Verbanac D, Zanetti M, Romeo D. Chemotactic and protease-inhibiting activities of antibiotic peptide precursors. FEBS Lett 1993; 371: 255–258
   Web of Science ®Google Scholar
• Huang HJ, Ross CR, Blecha F. Chemoattractant properties of PR-39, a neutrophil antibacterial peptide. J Leukoc Biol 1997; 61: 624–629
   PubMed Web of Science ®Google Scholar
• Yang D, Chen Q, Schmidt AP, et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 2000; 192: 1069–1074
   PubMed Web of Science ®Google Scholar
• Agerberth B, Charo J, Werr J, et al. The human antimicrobial and chemotactic peptides LL-37 and a-defensins are expressed by specific lymphocyte and monocyte populations. Blood 2000; 96: 3086–3093
   PubMed Web of Science ®Google Scholar
• Niyonsaba F, Iwabuchi K, Someya A, et al. A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. Immunology 2002; 106: 20–26
   PubMed Web of Science ®Google Scholar
• Kurosaka K, Chen Q, Yarovinsky F, Oppenheim JJ, Yang D. Mouse cathelin-related antimicrobial peptide chemoattracts leukocytes using formyl peptide receptor-like 1/mouse formyl peptide receptor-like 2 as the receptor and acts as an immune adjuvant. J Immunol 2005; 174: 6257–6265
   PubMed Web of Science ®Google Scholar
• Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock REW. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune response. J Immunol 2002; 169: 3883–3891
   PubMed Web of Science ®Google Scholar
• Koczulla R, von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 2003; 111: 1665–1672
   PubMed Web of Science ®Google Scholar
• Heilborn JD, Nilsson MF, Kratz G, et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol 2003; 120: 379–389
   PubMed Web of Science ®Google Scholar
• Elssner A, Duncan M, Gavrilin M, Wewers MD. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1b processing and release. J Immunol 2004; 172: 4987–4994
   PubMed Web of Science ®Google Scholar
• Nagaoka I, Tamura H, Hirata M. An antimicrobial cathelicidin peptide, human CAP18/LL-37, suppresses neutrophil apoptosis via the activation of formyl-peptide receptor-like 1 and P2X7. J Immunol 2006; 176: 3044–3052
   PubMed Web of Science ®Google Scholar
• Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007; 449: 564–569
   PubMed Web of Science ®Google Scholar
• Rosenberg HF, Tenen DG, Ackerman SJ. Molecular cloning of human eosinophil-derived neurotoxin: a member of the ribonuclease gene family. Proc Natl Acad Sci USA 1989; 86: 4460–4464
   PubMed Web of Science ®Google Scholar
• Mosimann SC, Newton DL, Youle RJ, James MN. X-ray crystallographic structure of recombinant eosinophil-derived neurotoxin at 1.83 A resolution. J Mol Biol 1996; 26: 540–552
   Web of Science ®Google Scholar
• Sur S, Glitz DG, Kita H, et al. Localization of eosinophil-derived neurotoxin and eosinophil cationic protein in neutrophilic leukocytes. J Leukoc Biol 1998; 63: 715–722
   PubMed Web of Science ®Google Scholar
• Egesten A, Dyer KD, Batten D, Domachowske JB, Rosenberg HF. Ribonucleases and host defense: identification, localization and gene expression in adherent monocytes in vitro. Biochim Biophys Acta 1997; 1358: 255–260
   PubMed Web of Science ®Google Scholar
• Domachowske JB, Dyer KD, Bonville CA, Rosenberg HF. Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. J Infect Dis 1998; 177: 1458–1464
   PubMed Web of Science ®Google Scholar
• Rugeles MT, Trubey CM, Bedoya VI, et al. Ribonuclease is partly responsible for the HIV-1 inhibitory effect activated by HLA alloantigen recognition. AIDS 2003; 17: 481–486
   PubMed Web of Science ®Google Scholar
• Yang D, Rosenberg HF, Chen Q, et al. Eosinophil-derived neurotoxin (EDN), an antimicrobial protein with chemotactic activities for dendritic cells. Blood 2003; 102: 3396–3403
   PubMed Web of Science ®Google Scholar
• Yang D, Chen Q, Su SB, et al. Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2-MyD88 signal pathway in dendritic cells and enhances Th2 immune responses. J Exp Med 2008; 205: 79–90
   PubMed Web of Science ®Google Scholar
• Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248–251
   PubMed Web of Science ®Google Scholar
• Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191–195
   PubMed Web of Science ®Google Scholar
• Bonaldi T, Talamo F, Scaffidi P, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. Embo J 2003; 22: 5551–5560
   PubMed Web of Science ®Google Scholar
• Rendon-Mitchell B, Ochani M, Li J, et al. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol 2003; 170: 3890–3897
   PubMed Web of Science ®Google Scholar
• Dumitriu IE, Baruah P, Valentinis B, et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 2005; 174: 7506–7515
   PubMed Web of Science ®Google Scholar
• Semino C, Angelini G, Poggi A, Rubartelli A. NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood 2005; 106: 609–616
   PubMed Web of Science ®Google Scholar
• Yang D, Chen Q, Yang H, et al. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol 2007; 81: 59–66
   PubMed Web of Science ®Google Scholar
• Messmer D, Yang H, Telusma G, et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 2004; 173: 307–313
   PubMed Web of Science ®Google Scholar
• Rouhiainen A, Kuja-Panula J, Wilkman E, et al. Regulation of monocyte migration by amphoterin (HMGB1). Blood 2004; 104: 1174–1182
   PubMed Web of Science ®Google Scholar
• Kokkola R, Andersson A, Mullins G, et al. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 2005; 61: 1–9
   PubMed Web of Science ®Google Scholar
• Rovere-Querini P, Capobianco A, Scaffidi P, et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004; 5: 825–830
   PubMed Web of Science ®Google Scholar
• Palumbo R, Sampaolesi M, De Marchis F, et al. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 2004; 164: 441–449
   PubMed Web of Science ®Google Scholar
• Park JS, Gamboni-Robertson F, He Q, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006; 290: C917–924
   PubMed Web of Science ®Google Scholar
• Tian J, Avalos AM, Mao SY, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007; 8: 487–496
   PubMed Web of Science ®Google Scholar
• Ivanov S, Dragoi AM, Wang X, et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 2007; 110: 1970–1981
   PubMed Web of Science ®Google Scholar
• Zetterstrom CK, Bergman T, Rynnel-Dagoo B, et al. High mobility group box chromosomal protein 1 (HMGB1) is an antibacterial factor produced by the human adenoid. Pediatr Res 2002; 52: 148–154
   PubMed Web of Science ®Google Scholar
• Kim C, Gajendran N, Mittrucker HW, et al. Human alpha-defensins neutralize anthrax lethal toxin and protect against its fatal consequences. Proc Natl Acad Sci USA 2005; 102: 4830–4835
   PubMed Web of Science ®Google Scholar
• Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 2006; 311: 17–58
   PubMed Web of Science ®Google Scholar
• Lillard JW, Jr, Boyaka PN, Chertov O, Oppenheim JJ, McGhee JR. Mechanisms for induction of acquired host immunity by neutrophil peptide defensins. Proc Natl Acad Sci USA 1999; 96: 651–656
   PubMed Web of Science ®Google Scholar
• Biragyn A, Ruffini PA, Coscia M, et al. Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood 2004; 104: 1961–1969
   PubMed Web of Science ®Google Scholar
• Wilson CL, Ouellette AJ, Satchell DP, et al. Regulation of intestinal a-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 1999; 286: 113–117
   PubMed Web of Science ®Google Scholar
• Morrison G, Kilanowski F, Davidson D, Dorin J. Characterization of the mouse b defensin 1, Defb1, mutant mouse model. Infect Immun 2002; 70: 3053–3060
   PubMed Web of Science ®Google Scholar
• Moser C, Weiner DJ, Lysenko E, et al. b-Defensin 1 contributes to pulmonary innate immunity in mice. Infect Immun 2002; 70: 3068–3072
   PubMed Web of Science ®Google Scholar
• Nizet V, Ohtake T, Lauth X, et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 2001; 414: 454–457
   PubMed Web of Science ®Google Scholar
• Salzman NH, Ghosh D, Huttner KM, Paterson Y, Bevins CL. Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. Nature 2003; 422: 522–526
   PubMed Web of Science ®Google Scholar
• Bals R, Weiner DJ, Meegalla RL, Wilson JM. Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. J Clin Invest 1999; 103: 1113–1117
   PubMed Web of Science ®Google Scholar
• Bals R, Weiner DJ, Moscioni AD, Meegalla RL, Wilson JM. Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect Immun 1999; 67: 6084–6089
   PubMed Web of Science ®Google Scholar
• Welling MM, Hiemstra PS, van-den-Barselaar MT, et al. Antibacterial activity of human neutrophil defensins in experimental infections in mice is accompanied by increased leukocyte accumulation. J Clin Invest 1998; 102: 1583–1590
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Stevens DA, Denning DW, Moss RB. Advances against aspergillosis. Clin Infect Dis 2003; 37: S155–S156
   Web of Science ®Google Scholar
• Philippe B, Ibrahim-Granet O, Prevost MC, et al. Killing of Aspergillus fumigatus by alveolar macrophages is mediated by reactive oxidant intermediates. Infect Immun 2003; 71: 3034–3042
   PubMed Web of Science ®Google Scholar
• Schaffner A, Douglas H, Braude A. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. J Clin Invest 1982; 69: 617–631
   PubMed Web of Science ®Google Scholar
• Bozza S, Perruccio K, Montagnoli C, et al. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood 2003; 102: 3807–3814
   PubMed Web of Science ®Google Scholar
• Cenci E, Mencacci A, Fe d'Ostiani C, et al. Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. J Infect Dis 1998; 178: 1750–1760
   PubMed Web of Science ®Google Scholar
• Harder J, Bartels J, Christophers E, Schröder JM. Isolation and characterization of human b-defensin-3, a novel human inducible peptide antibiotics. J Biol Chem 2001; 276: 5707–5713
   PubMed Web of Science ®Google Scholar
• Simon A, Kullberg BJ, Tripet B, et al. Drosomycin-like defensin (DLD): a human homologue of Drosophila melanogaster drosomycin with antifungal activity. Antimicrob Agents Chemother 2008; 52: 1407–1412
   PubMed Web of Science ®Google Scholar